Insight Brief

Get instant access

The numbers tell the story: in the U.S., the economic burden of neurological disorders is a staggering $800 billion annually. This fact, coupled with diminishing development success rates for CNS therapies, requires new and innovative ways of thinking about CNS drug development in complex Phase I trials.

Discover how to improve success rates and advance your CNS asset as rapidly as possible through novel approaches to Phase I studies.